LakeShore Biopharma Co., Ltd Total Assets
LakeShore Biopharma Co., Ltd total assets. Based on the latest financial reports, LakeShore Biopharma Co., Ltd (LSBCF) holds total assets worth $1.37 Billion USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LakeShore Biopharma Co., Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of LakeShore Biopharma Co., Ltd (2021–2025)
Total assets of LakeShore Biopharma Co., Ltd from 2021 to 2025. This chart illustrates how LakeShore Biopharma Co., Ltd's total assets have evolved over time, based on quarterly financial data. See LSBCF stock price for real-time trading data and today's change.
LakeShore Biopharma Co., Ltd - Asset Composition Analysis
LakeShore Biopharma Co., Ltd Total Assets Breakdown (March 2025)
LakeShore Biopharma Co., Ltd total assets breakdown as of March 2025. LakeShore Biopharma Co., Ltd's total assets of $1.37 Billion consist of 61.6% current assets and 38.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.1% |
| Accounts Receivable | $501.79 Million | 36.7% |
| Inventory | $227.59 Million | 16.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $72.85 Million | 5.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how LakeShore Biopharma Co., Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore LakeShore Biopharma Co., Ltd (LSBCF) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LakeShore Biopharma Co., Ltd's current assets represent 61.6% of total assets in 2025, a decrease from 802421.1% in 2021.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2025, down from 427317.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 91687.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 36.7% of total assets.
LakeShore Biopharma Co., Ltd Competitors by Total Assets
Key competitors of LakeShore Biopharma Co., Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
LakeShore Biopharma Co., Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 1.13 | 2.77 |
| Quick Ratio | 0.75 | 0.87 | 2.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.47 Million | $100.94 Million | $8.98 Million |
LakeShore Biopharma Co., Ltd - Advanced Valuation Insights
This section examines the relationship between LakeShore Biopharma Co., Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.04 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -9.6% |
| Total Assets | $1.37 Billion |
| Market Capitalization | $2.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values LakeShore Biopharma Co., Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LakeShore Biopharma Co., Ltd's assets decreased by 9.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LakeShore Biopharma Co., Ltd (2021–2025)
The table below shows the annual total assets of LakeShore Biopharma Co., Ltd from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $1.37 Billion | -9.61% |
| 2024-03-31 | $1.51 Billion | -12.02% |
| 2023-03-31 | $1.72 Billion | +755.45% |
| 2022-03-31 | $201.03 Million | +219912.42% |
| 2021-03-31 | $91.37K | -- |
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS… Read more